Immuno and enzymatic assays
The ELISA and enzymatic techniques are the standards in neonatal screening. These techniques enable the detection of metabolic and endocrine diseases that may cause developmental delays, or even death, in infants. With early detection, prompt management can be implemented, thereby maximizing the newborn’s chances of growing and developing normally.
To cater for the needs of each type of laboratory, regardless of size, manual or automated kits are available.
The NEONATAL BTD Screening Fluo is an enzymatic assay designed to quantitatively measure biotinidase (BTD) activity levels in newborns, using dried blood spots, for the detection of biotinidase deficiency.
The NEONATAL 17-OHP Screening FLISA is a fluorescent enzyme immunoassay designed for the quantitative measurement of 17 alpha-hydroxyprogesterone (17-OHP).
The NEONATAL TSH Screening FLISA is a fluorescent enzyme immunoassay designed for the quantitative measurement of thyroid stimulating hormone (TSH).
Cystic Fibrosis IRT
The NEONATAL IRT Screening FLISA is a fluorescent enzyme immunoassay for the quantitative determination of immunoreactive trypsinogen (IRT).
Fluo
G6PD Deficiency
The NEONATAL G-6-PD Screening Fluo is an enzymatic assay designed for the precise quantitative measurement of G-6-PD activity, aiding in the detection of G-6-PD deficiency.
Fluo
Galactosemia GALT
The NEONATAL GAL-T Screening Fluo is an enzymatic assay for the quantitative determination of galactose-1-phosphate uridyltransferase (GAL-T) activity levels.
Fluo
Galactosemia TGAL
The NEONATAL T-GAL Screening Fluo is an enzymatic test for the fluorescence detection of D-galactose and galactose-1-phosphate in the context of neonatal screening for galactosemia.
Fluo
The NEONATAL MSUD Screening Fluo is an enzymatic test which enables the fluorescence detection of 3 amino acids (leucine, isoleucine and valine) accumulated in case of maple syrup urine disease (MSUD) in newborns.
Phenylketonuria
The NEONATAL PKU Screening Fluo is an enzymatic test designed to screen newborns affected by phenylketonuria.
Fluo
qPCR
Analysis Our molecular line screens for SMA, SCID and XLA by multiplex qPCR.
Run separately or as a single SCID + SMA + XLA reaction, directly from one dried blood spot. One punch, up to three actionable results.
Analysis Our molecular line screens for SMA, SCID and XLA by multiplex qPCR.
Run separately or as a single SCID + SMA + XLA reaction, directly from one dried blood spot. One punch, up to three actionable results.
Mass
spectrometry Our mass spectrometry line resolves clinically significant hemoglobin variants with MS/MS sensitivity. Sample multiplexing keeps throughput high for large-scale programmes.
spectrometry Our mass spectrometry line resolves clinically significant hemoglobin variants with MS/MS sensitivity. Sample multiplexing keeps throughput high for large-scale programmes.
Digital Microfluidics
Our digital microfluidics (DMF) line measures enzyme activity to screen for lysosomal storage diseases - multiplexed screening from very small volumes on a compact and user-friendly platform.
You have a question regarding our products ? You want to know more about our method ?
Find out about our other expertises
Genetic testing
CE Kits
Pharmacogenetics
Genetic testing
CE Kits
Genetic predispositions and disorders
